Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 8/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935059 | 0.88 | MAPT (0.66) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1935058 | 0.88 | MAPT (0.66) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5434236 | 0.88 | MAPT (0.66) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29400871 | 0.84 | PPARG (0.51) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL31490548 | 0.84 | BCL9 (0.52) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11094615 | 0.83 | MAPT (0.50) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9807290 | 0.83 | MAPT (0.50) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7385206 | 0.83 | MAPT (0.50) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6473599 | 0.82 | PPARG (0.52) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6440284 | 0.81 | CTSL (0.57) | GAAAAK1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171516-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171516-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 2241/4885MAPT 2772/4885SMN1; SMN2 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.